Gyre Therapeutics (NASDAQ:GYRE) Shares Up 6.7%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shot up 6.7% during trading on Monday . The stock traded as high as $11.29 and last traded at $11.10. 12,653 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 75,727 shares. The stock had previously closed at $10.40.

Gyre Therapeutics Stock Up 4.1 %

The firm’s 50 day moving average is $12.17 and its 200 day moving average is $14.53.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The firm had revenue of $27.17 million during the quarter. As a group, analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Activity at Gyre Therapeutics

In related news, Director Nassim Usman sold 3,452 shares of Gyre Therapeutics stock in a transaction on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the sale, the director now owns 1,636 shares in the company, valued at $19,632. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.92% of the stock is currently owned by company insiders.

Institutional Trading of Gyre Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new stake in Gyre Therapeutics in the second quarter valued at $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $166,000. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $218,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $220,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.